U.S. Food, Drug, and Cosmetic Act

U.S. Food, Drug, and Cosmetic Act
Name	U.S. Food, Drug, and Cosmetic Act
Enacted by	United States Congress
Effective	1938
Signed by	Franklin D. Roosevelt
Short title	FD&C Act
Long title	An Act to prevent the adulteration and misbranding of foods, drugs, and cosmetics.

U.S. Food, Drug, and Cosmetic Act

The U.S. Food, Drug, and Cosmetic Act is a federal statute enacted in 1938 that overhauled prior Pure Food and Drug Act of 1906 standards and expanded regulatory authority over drugs, devices, food, and cosmetics. Prompted by public outcry following the Elixir Sulfanilamide disaster and legislative pressure from figures such as Harvey W. Wiley advocates and members of the United States House of Representatives, the Act established foundation for the Food and Drug Administration, codified labeling requirements, and created civil and criminal penalties enforced by federal agencies and courts.

History and enactment

Congress drafted the Act in response to tragedies like the Elixir Sulfanilamide disaster and investigative journalism in publications such as Collier's and reports connected to reformers allied with Muckrakers and committees of the United States Senate. Debates involved stakeholders including representatives from the American Medical Association, the National Consumers League, and industry groups such as the Pharmaceutical Research and Manufacturers of America and National Food Processors Association. Passage required negotiation between the United States Senate Committee on Interstate and Foreign Commerce and the United States House Committee on Interstate and Foreign Commerce and culminated in a signature by Franklin D. Roosevelt after revisions addressing concerns raised by attorneys from the Department of Justice and counsel to the White House.

Key provisions and definitions

The Act defined standards for "adulteration" and "misbranding" that affected manufacturers like Pfizer, Johnson & Johnson, and Kellogg Company. It required premarket approval pathways affecting entities such as Eli Lilly and Company and devices later regulated under the Act's device sections impacting firms like Medtronic. Labeling and safety definitions shaped food standards influenced by agencies including the United States Department of Agriculture and later intersected with international rules from the Codex Alimentarius Commission. Controlled provisions introduced statutory authority used in enforcement actions involving corporations like Bayer and Merck & Co..

Regulatory authority and enforcement

The Act empowered the Food and Drug Administration to inspect facilities, seize products, and seek injunctions in federal courts such as the United States District Court for the District of Columbia and the United States Court of Appeals for the D.C. Circuit. Enforcement involved coordination with the Federal Trade Commission on advertising matters and with the Department of Justice for criminal prosecutions. Oversight intersected with agencies including the Centers for Disease Control and Prevention during outbreak investigations and the National Institutes of Health on clinical research standards overseen by Institutional Review Boards guided by authorities like OHRP (Office for Human Research Protections).

Amendments and major amendments timeline

Major amendments include the Durham–Humphrey Amendment (1951) which clarified prescription drug status affecting pharmacies like CVS Health; the Kefauver Harris Amendment (1962) which introduced efficacy requirements influenced by hearings led by Senator Estes Kefauver and sponsor Representative Oren Harris; the Medical Device Amendments of 1976 which created device classification used in disputes involving Stryker Corporation; the Food Additives Amendment (1958) establishing GRAS standards and involving companies such as Kraft Foods; and the Orphan Drug Act (1983) which created incentives affecting Genzyme and biotechnology firms like Amgen. Subsequent laws including the Prescription Drug User Fee Act (1992), the Food Safety Modernization Act (2011), and the 21st Century Cures Act (2016) further modified regulatory pathways used by entities such as FDA-regulated sponsors and research institutions like Johns Hopkins University and Massachusetts General Hospital.

Impact on industry and public health

The statute reshaped pharmaceutical development for firms including GlaxoSmithKline and Novartis by establishing clinical trial and labeling standards that reduced risks exemplified by past incidents like the Thalidomide tragedy in Europe. Food industry practices at corporations such as Nestlé and Conagra Brands adapted to inspection and labeling requirements that influenced international trade with partners like the European Union and regulators such as the European Medicines Agency. Public health surveillance by agencies including the Centers for Disease Control and Prevention and the World Health Organization leveraged the Act's reporting and recall mechanisms during outbreaks such as Salmonella and E. coli recalls that affected companies like JBS USA and Kroger.

Litigation and notable court cases

Judicial review shaped interpretation in cases like United States v. Dotterweich and United States v. Park which affirmed corporate responsibility doctrines and criminal liability for executives in the Supreme Court of the United States. The Kefauver Harris Amendment led to litigation concerning drug approval standards addressed in federal appellate decisions such as those from the United States Court of Appeals for the First Circuit. Cases including Wyeth v. Levine later examined preemption and labeling responsibilities impacting manufacturers like Wyeth Pharmaceuticals (now part of Pfizer). Antitrust and False Claims Act litigation involving drug pricing and Medicare reimbursement engaged entities such as Johnson & Johnson, Novartis, and enforcement by the United States Department of Justice.

Category:United States federal health legislation